<DOC>
	<DOCNO>NCT02047110</DOCNO>
	<brief_summary>The overall purpose trial ass clinical efficacy three different subcutaneous dos BI 655066 adult patient AS , order provide clinical proof concept select dose ( ) confirmatory clinical trial .</brief_summary>
	<brief_title>BI 655066 Proof Concept Dose Finding Study Ankylosing Spondylitis ( AS )</brief_title>
	<detailed_description />
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<criteria>Inclusion criterion : 1 . Male female patient 2 . Age = 18 year = 70 year 3 . Definite AS base modify New York criterion ( 1984 ) 4 . Documented disease duration &gt; = 3 month screen 5 . Active disease screening , define : 1 . BASDAI score ( 010 ) &gt; = 4 , AND 2 . Spinal pain level assess 2nd BASDAI question ( 010 ) &gt; = 4 6 . Have either document inadequate response axial symptom 30 day optimal daily dos least two nonsteroidal antiinflammatory drug ( NSAIDs ) , document intolerance NSAIDs 7 . Female patient meet follow criterion screen visit End Observation visit ( EOO ) : use adequate contraception , e.g . follow method plus condom : implant , injectables , combine oral contraceptive , intrauterine device ( IUD ) sexually abstinent vasectomised sexual partner ( vasectomy least 1 year prior enrolment ) surgically sterilise ( include hysterectomy ) postmenopausal define least 1 year spontaneous Amenorrhea 8 . Patients ( male female ) receive background MTX Leflunomide therapy follow national regulatory guideline regard contraception 9 . Signed date write informed consent prior admission study accordance GCP local legislation Exclusion criterion : 1 . Radiographic evidence total ankylosis spine screening ( spinal XRay examination screen visit/ screening period mandatory Â¿ see footnote 12 FlowChart 1 ) 2 . Patient previously treat biological immunomodulating agent AS , either license experimental 3 . Previous current participation clinical trial test investigational drug AS within 12 week prior randomization ( biological immunomodulating agent exclude ) 4 . Usage investigational drug within 30 day prior randomization plan use investigational drug course actual study 5 . Active uveitis inflammatory bowel disease screen 6 . Diagnosed psoriatic arthritis screening , satisfy modify New York criteria 7 . Patients receive intraarticular injection ( ) corticosteroid within 4 week prior screen visit 8 . Patients must wish continue intake restricted medication ( cf . Section 4.2.2.1 ) drug consider likely interfere safe conduct study 9 . Major surgery perform within 8 week prior screen plan within 12 month screen ( e.g . hip replacement ) 10 . Chronic relevant acute infection include HIV , viral hepatitis tuberculosis ( positive test HIV , HBV/HCV screen exclusionary ) For tuberculosis patient , eligible accord follow screen criterion : Have sign symptom suggestive current active latent TB upon medical history , physical examination and/or chest radiograph ( posterioranterior lateral view , take within 3 month prior first administration study drug read qualified radiologist ) Have history latent active TB prior screen , except patient documentation complete adequate treatment regimen least 6 month prior first administration study agent Have positive QuantiFERONTB Gold InTube test within 2 month prior screen , active TB rule , except patient history latent TB documentation complete adequate treatment regimen least 6 month prior first administration study agent 11 . Any documented active suspect malignancy history malignancy within 5 year prior screen , except appropriately treat basal cell carcinoma skin situ carcinoma uterine cervix 12 . Evidence current previous clinically significant disease , medical condition AS , find medical examination ( include vital sign ECG ) , laboratory value screen visit outside reference range clinical relevance , opinion Investigator , would compromise safety patient quality data . This criterion provide opportunity investigator exclude patient base clinical judgment , even eligibility criterion satisfy . 13 . History allergy/hypersensitivity systemically administer biologic agent excipients 14 . History alcohol abuse within last 12 month ( intake 30 g/day ) 15 . History drug abuse within last 12 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>ABBV-066</keyword>
	<keyword>BI 655066</keyword>
	<keyword>risankizumab</keyword>
</DOC>